Nov. 21, 2023—Researchers at Vanderbilt University Medical Center for the first time have shown that activation of the epidermal growth factor receptor (EGFR) is essential for the development of kidney fibrosis, tissue scarring following injury that can lead to kidney failure.
Nov. 17, 2022—In December Vanderbilt University Medical Center will again update the equation used for estimating kidney function with the goals of improving health equity and better guiding patient care decisions.
Nov. 17, 2022—An in-depth analysis by Vanderbilt investigators of published research studies supports removing race from the calculation of estimated glomerular filtration rate (eGFR) — an assessment of kidney function.
Jul. 28, 2022—A Vanderbilt study suggests that clinicians should take a deeper dive into distinguishing EGFR mutations when prescribing targeted therapies for non-small-cell lung cancers.
Apr. 7, 2022—The protein CGA — a subunit of glycoprotein hormones — is a biomarker that predicts chemoresistance in gastric cancer and could be targeted along with EGFR to restore chemosensitivity.
Jul. 30, 2020—A protein linked to amyotrophic lateral sclerosis (ALS), a progressive neurological disease that causes muscle weakness, may be a key to treating fibrotic disease of the kidneys and other organs, researchers at Vanderbilt University Medical Center reported recently.
Jul. 13, 2020—A group of Vanderbilt students, residents and faculty — connected through their passion for health equity — have identified and worked together to rectify longstanding concerns about the inappropriate use of race as a variable in the calculation of estimated glomerular filtration rate (eGFR), which estimates a patient’s level of kidney function and helps determine the stage of kidney disease.